Quantitative Assessment of the Heterogeneity of PD-L1 Cancer

Citation Report

#	Article	IF	Citations
1	Current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 196-211.	1.3	150
2	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. , 2015, 3, 58.		26
3	Clinical significance of *PD-L1* and *PD-L2* copy number gains in non-small-cell lung cancer. Oncotarget, 2016, 7, 32113-32128.	0.8	100
4	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. Cancer Biology and Medicine, 2016, 13, 157-170.	1.4	86
5	New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics: Targets and Therapy, 2016, Volume 10, 103-117.	3.0	23
6	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget, 2016, 7, 32925-32932.	0.8	248
7	Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 298-308.	1.8	115
8	Biomarkers for Immunotherapy: Current Developments and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e493-e503.	1.8	85
9	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Translational Lung Cancer Research, 2016, 5, 720-726.	1.3	32
10	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	0.8	100
11	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. International Journal of Molecular Sciences, 2016, 17, 790.	1.8	32
12	PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. International Journal of Molecular Sciences, 2016, 17, 1046.	1.8	20
13	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 2016, 11, 385-390.	0.8	20,872
15	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. ESMO Open, 2016, 1, e000083.	2.0	61
16	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. Journal of Translational Medicine, 2016, 14, 173.	1.8	103
17	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
18	Targeting PD-L1 for non-small-cell lung cancer. Immunotherapy, 2016, 8, 747-758.	1.0	12
19	Into the Clinic With Nivolumab and Pembrolizumab. Oncologist, 2016, 21, 527-528.	1.9	17

#	ARTICLE	IF	CITATIONS
20	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	1.3	30
21	Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 2016, 48, 574-580.	0.3	59
22	Relationship of tumor PD-L1 expression with *EGFR* wild-type status and poor prognosis in lung adenocarcinoma. Japanese Journal of Clinical Oncology, 2016, 46, 935-941.	0.6	49
23	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunology, Immunotherapy, 2016, 65, 1511-1522.	2.0	17
25	Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select. Journal of Clinical Oncology, 2016, 34, 3115-3116.	0.8	16
26	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Journal of Thoracic Oncology, 2016, 11, 1869-1878.	0.5	81
27	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	6.3	132
28	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 2016, 11, 1993-2005.	0.5	96
29	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology, 2016, 29, 1552-1564.	2.9	25
30	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Annals of Oncology, 2016, 27, 1953-1958.	0.6	289
31	EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1901-1911.	0.5	14
32	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology, 2016, 58, 7-14.	1.1	135
33	Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs, 2016, 30, 397-405.	2.2	36
34	The pathway to clinical use of a cancer biomarker. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S17-S21.	0.6	3
35	Making urothelial carcinomas less immune to immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 534-537.	0.8	2
36	Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. OncoImmunology, 2016, 5, e1248327.	2.1	60
37	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
38	Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1727-1738.	1.2	73

#	Article	IF	Citations
39	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Current Treatment Options in Oncology, 2016, 17, 40.	1.3	34
40	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	0.5	31
41	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer, 2016, 97, 73-80.	0.9	122
42	Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 3713-3717.	3.2	62
43	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 1217.	3.4	216
44	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non–Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 569.	3.4	5
45	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. Archives of Pathology and Laboratory Medicine, 2016, 140, 351-354.	1.2	12
46	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. Archives of Pathology and Laboratory Medicine, 2016, 140, 326-331.	1.2	118
47	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 511-525.	1.4	212
49	Molecular pathology in real time. Cancer and Metastasis Reviews, 2016, 35, 129-140.	2.7	26
50	Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 976-988.	0.5	197
51	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research, 2016, 22, 2102-2104.	3.2	31
52	Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-Related Cancer, 2017, 24, 97-106.	1.6	119
53	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Modern Pathology, 2017, 30, 530-538.	2.9	92
54	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Modern Pathology, 2017, 30, 577-586.	2.9	132
55	Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. Gynecologic Oncology, 2017, 144, 607-612.	0.6	61
56	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. OncoImmunology, 2017, 6, e1279777.	2.1	50
57	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 3585-3591.	3.2	264

#	Article	IF	Citations
58	Immunoprofiling as a predictor of patient's response to cancer therapy—promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
59	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. European Journal of Cancer, 2017, 75, 141-149.	1.3	84
60	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 4270-4279.	3.2	117
62	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	0.5	20
64	Assays for PD-L1 Expression. JAMA Oncology, 2017, 3, 1058.	3.4	4
65	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology, 2017, 6, e1278100.	2.1	65
66	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2017, 18, 572-582.e1.	1.1	46
67	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944.	3.2	120
68	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes and Cancer, 2017, 56, 651-659.	1.5	35
69	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. American Journal of Surgical Pathology, 2017, 41, 334-342.	2.1	143
70	PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. American Journal of Surgical Pathology, 2017, 41, 326-333.	2.1	113
71	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. Respiration, 2017, 93, 1-14.	1.2	7
72	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Annals of the American Thoracic Society, 2017, 14, 1248-1260.	1.5	15
73	Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. OncoImmunology, 2017, 6, e1329071.	2.1	85
74	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 70, 34-42.	0.8	38
75	Clinical applications of PD-L1 bioassays for cancer immunotherapy. Journal of Hematology and Oncology, 2017, 10, 110.	6.9	66
76	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology, 2017, 19, 1058-1067.	0.6	38
77	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Research, 2017, 5, 12.	2.8	149

#	Article	IF	Citations
78	Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epsteinâ€"Barr virus-associated gastric cancer: the prognostic implications. Modern Pathology, 2017, 30, 427-439.	2.9	130
79	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. OncoImmunology, 2017, 6, e1260214.	2.1	11
80	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
81	The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer, 2017, 104, 7-15.	0.9	69
82	PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?. Expert Review of Molecular Diagnostics, 2017, 17, 1097-1108.	1.5	31
83	PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. Radiology and Oncology, 2017, 51, 357-362.	0.6	40
84	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open, 2017, 2, e000236.	2.0	30
85	Metabolic characteristics of programmed cell deathâ€"ligand 1â€"expressing lung cancer on ¹⁸Fâ€"fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Medicine, 2017, 6, 2552-2561.	1.3	80
86	PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer, 2017, 113, 102-105.	0.9	34
87	PDâ€‘L1 expression in nonâ€"small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathology, 2017, 125, 896-907.	1.4	164
88	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. Expert Review of Molecular Diagnostics, 2017, 17, 1055-1069.	1.5	24
89	Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells. Cellular Physiology and Biochemistry, 2017, 43, 1893-1906.	1.1	65
90	PDL-1/PD1 inhibitors: antibody or antinobody?. Future Oncology, 2017, 13, 1669-1671.	1.1	7
91	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications, 2017, 8, 606.	5.8	89
92	Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis. Bulletin Du Cancer, 2017, 104, 675-682.	0.6	8
93	PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions. Gynecologic Oncology Reports, 2017, 20, 135-136.	0.3	1
94	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCCâ€"a computational study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 157-164.	0.2	8
95	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1536-1543.	0.5	53

#	Article	IF	Citations
96	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. OncoImmunology, 2017, 6, e1356146.	2.1	27
97	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer, 2017, 112, 200-215.	0.9	213
98	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, 2017, 19, 64.	1.8	106
99	Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479.	1.1	35
100	Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 859-862.	2.3	12
101	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Human Pathology, 2017, 66, 13-33.	1.1	46
102	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	12.5	787
103	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
104	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunology, Immunotherapy, 2017, 66, 33-43.	2.0	30
105	The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54.	4.0	21
106	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Modern Pathology, 2017, 30, 340-349.	2.9	138
107	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends in Pharmacological Sciences, 2017, 38, 25-40.	4.0	87
108	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology, 2017, 3, 256.	3.4	164
109	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology, 2017, 70, 253-263.	1.6	37
110	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. Molecular Diagnosis and Therapy, 2017, 21, 85-93.	1.6	28
111	Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8.	1.1	72
112	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research, 2017, 23, 370-378.	3.2	150
114	Programmed death ligand 1 (pd-l1) expression in malignant mesenchymal tumors. Turk Patoloji Dergisi, 2017, 1, 192-197.	0.1	16

#	Article	IF	Citations
115	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. BioMed Research International, 2017, 2017, 1-8.	0.9	13
116	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 67.	1.3	28
117	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. OncoTargets and Therapy, 2017, Volume 10, 3697-3708.	1.0	6
118	Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE, 2017, 12, e0183023.	1.1	73
119	Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS ONE, 2017, 12, e0186192.	1.1	49
120	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, 2017, 17, 690.	1.1	41
121	AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Research, 2017, 19, 88.	2.2	25
122	Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research, 2017, 19, 91.	2.2	90
123	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
124	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer, 2017, 36, 61.	4.9	42
125	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance. Journal of Biomedical Sciencies, 2017, 06, .	0.3	0
126	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget, 2017, 8, 98524-98532.	0.8	40
127	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence *in situ* hybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget, 2017, 8, 100863-100898.	0.8	16
128	The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung. Oncology Reports, 2017, 38, 2189-2196.	1.2	5
129	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?. Journal of Thoracic Disease, 2017, 9, E519-E521.	0.6	3
130	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. OncoImmunology, 2018, 7, e1438111.	2.1	119
131	Clinical performance of endobronchial ultrasound–guided transbronchial needle aspiration for assessing programmed death ligand–1 expression in nonsmall cell lung cancer. Diagnostic Cytopathology, 2018, 46, 378-383.	0.5	38
132	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. OncoImmunology, 2018, 7, e1442168.	2.1	64

#	ARTICLE	IF	CITATIONS
133	Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathology, 2018, 126, 342-352.	1.4	102
134	Programmed death–ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Science, 2018, 109, 814-820.	1.7	31
136	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	0.9	29
137	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open, 2018, 3, e000344.	2.0	105
138	PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876349.	1.4	120
139	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer, 2018, 19, e421-e430.	1.1	53
141	Contraction of T cell richness in lung cancer brain metastases. Scientific Reports, 2018, 8, 2171.	1.6	74
142	Cytologic–histologic correlation of programmed death–ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathology, 2018, 126, 253-263.	1.4	70
144	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Scientific Reports, 2018, 8, 1922.	1.6	108
145	Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775007.	1.0	88
146	Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. Oncogene, 2018, 37, 2302-2312.	2.6	57
147	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell, 2018, 33, 187-201.e10.	7.7	381
149	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open, 2018, 3, e000257.	2.0	62
150	Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays. American Journal of Surgical Pathology, 2018, 42, 687-694.	2.1	31
151	PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock	1.0	90
152	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Modern Pathology, 2018, 31, 623-632.	2.9	102
153	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 367-376.	0.5	127
154	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23

#	Article	IF	Citations
155	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer. Radiology, 2018, 287, 326-332.	3.6	24
156	Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344.		0
157	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer, 2018, 116, 1-6.	0.9	51
158	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
159	The expression of programed death ligand–1 could be related with unfavorable prognosis in salivary duct carcinoma. Journal of Oral Pathology and Medicine, 2018, 47, 683-690.	1.4	28
160	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225.	1.1	28
161	PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology, 2018, 13, 12.	0.9	175
162	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, 1204-1212.	0.5	46
163	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66.	2.2	10
164	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. Molecular Cancer Therapeutics, 2018, 17, 1324-1331.	1.9	65
165	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. American Journal of Pathology, 2018, 188, 1478-1485.	1.9	119
166	Biomarker use in lung cancer management: expanding horizons. Biomarkers in Medicine, 2018, 12, 315-320.	0.6	2
167	Clinical and Molecular Predictors of PD-L1 Expression in Non–Small-Cell Lung Cancer: Systematic Review and Meta-analysis. Clinical Lung Cancer, 2018, 19, 315-322.	1.1	36
168	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. Journal of Clinical Pathology, 2018, 71, 46-51.	1.0	17
169	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	1.2	70
170	Programmed death–ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. Cancer Cytopathology, 2018, 126, 122-128.	1.4	60
171	Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 2018, 24, 407-419.	3.2	203
172	Immunotherapy and Lung Cancer. , 2018, , 501-511.e3.		2

#	ARTICLE	IF	CITATIONS
173	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
174	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology, 2018, 15, 112-124.	1.9	73
175	PD-L1. Journal of Clinical Pathology, 2018, 71, 189-194.	1.0	218
176	The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Clinical Lung Cancer, 2018, 19, 120-129.	1.1	61
177	Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab–treated patients with advanced non–small cell lung cancer. Cancer Medicine, 2018, 7, 13-20.	1.3	78
178	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology, 2018, 19, 303-317.	3.3	78
179	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Letters, 2018, 414, 166-173.	3.2	207
180	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Seminars in Cancer Biology, 2018, 52, 166-177.	4.3	11
181	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Molecular Diagnosis and Therapy, 2018, 22, 1-10.	1.6	139
182	Aligning digital CD8+ scoring and targeted next–generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early–stage squamous cell lung carcinoma. Histopathology, 2018, 72, 270-284.	1.6	17
183	PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 393-397.	0.6	12
184	*CD*274 (*PDL*1) and *JAK*2 genomic amplifications in pulmonary squamous–cell and adenocarcinoma patients. Histopathology, 2018, 72, 259-269.	1.6	27
185	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21, 31-40.	2.7	75
186	Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?. Journal of Clinical Oncology, 2018, 36, 631-632.	0.8	165
187	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. Journal of Gastrointestinal Oncology, 2018, 9, 610-617.	0.6	192
188	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 816-824.	0.6	9
189	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S995-S998.	0.6	1
190	Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4031-S4033.	0.6	3

#	ARTICLE	IF	CITATIONS
191	The clinical utility of tumor mutational burden in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 639-646.	1.3	98
192	High PDâ€L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncology Letters, 2019, 17, 1626-1634.	0.8	14
193	PD-1/PD-L1 expression in thymic epithelial tumors: the predicament persists. Mediastinum, 2018, 2, 60-60.	0.6	0
194	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
195	Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Nonâ€"Small Cell Lung Carcinomas. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 701-708.	0.6	26
196	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. PLoS ONE, 2018, 13, e0206370.	1.1	58
197	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer, 2018, 18, 1082.	1.1	42
198	89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	15.2	468
199	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Current Molecular Medicine, 2018, 17, 527-540.	0.6	20
200	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664.	5.8	331
201	Linear Endobronchial Ultrasound: What's New?. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 649-660.	0.8	5
202	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. Npj Breast Cancer, 2018, 4, 40.	2.3	36
203	The prognostic significance of circulating tumor cells in head and neck and nonâ€smallâ€cell lung cancer. Cancer Medicine, 2018, 7, 5910-5919.	1.3	91
204	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	38
205	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. Journal of Cancer, 2018, 9, 4325-4333.	1.2	16
206	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 167-174.	1.0	0
207	Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Cancer Immunology Research, 2018, 6, 1122-1128.	1.6	81
208	Diagnostic and Predictive Immunohistochemistry for Nonâ€"Small Cell Lung Carcinomas. Advances in Anatomic Pathology, 2018, 25, 374-386.	2.4	15

#	Article	IF	Citations
209	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews, 2018, 70, 232-244.	3.4	36
210	Role of noninvasive molecular imaging in determining response. Advances in Radiation Oncology, 2018, 3, 534-547.	0.6	25
211	Predictive biomarkers for tumor immune checkpoint blockade. Cancer Management and Research, 2018, Volume 10, 4501-4507.	0.9	18
212	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Journal of Thoracic Oncology, 2018, 13, 1884-1896.	0.5	78
214	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661879413.	1.0	35
215	The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncology, 2018, 86, 81-90.	0.8	95
216	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer. European Journal of Cancer, 2018, 103, 52-60.	1.3	16
217	Importance of choice of materials and methods in PD‐L1 and TIL assessment in oropharyngeal squamous cell carcinoma. Histopathology, 2018, 73, 500-509.	1.6	37
218	The Immune Landscape of Non–Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 24-38.	2.5	14
219	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661.	2.6	219
220	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. Anticancer Research, 2018, 38, 3789-3796.	0.5	64
221	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer, 2018, 122, 234-242.	0.9	22
222	The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer. BioMed Research International, 2018, 2018, 1-6.	0.9	32
223	Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. Human Pathology, 2018, 82, 282-288.	1.1	5
224	Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. Critical Reviews in Oncology/Hematology, 2018, 129, 133-145.	2.0	25
225	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Frontiers in Oncology, 2018, 8, 270.	1.3	47
226	Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis. Cancer Science, 2018, 109, 2957-2969.	1.7	30
227	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Frontiers in Medicine, 2018, 5, 85.	1.2	182

#	Article	IF	Citations
228	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science, 2018, 109, 2539-2548.	1.7	35
229	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	1.1	24
230	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Human Pathology, 2018, 82, 39-45.	1.1	2
231	Anti‐PD‐1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Medicine, 2018, 7, 2654-2664.	1.3	126
232	Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiation Oncology, 2018, 13, 10.	1.2	29
233	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology, 2018, 29, 2121-2128.	0.6	74
234	Can radiomics personalise immunotherapy?. Lancet Oncology, The, 2018, 19, 1138-1139.	5.1	25
235	Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. Healthcare (Switzerland), 2018, 6, 78.	1.0	3
236	Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer. Thoracic Cancer, 2018, 9, 1291-1299.	0.8	47
237	Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients. Clinical Genitourinary Cancer, 2018, 16, e1015-e1024.	0.9	12
238	Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer, 2018, 21, 1064-1070.	2.7	25
239	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 155-171.	4.2	25
240	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
241	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. Journal of Oncology Pharmacy Practice, 2019, 25, 663-673.	0.5	8
242	Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study. Clinical Lung Cancer, 2019, 20, 208-214.e2.	1.1	76
243	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS ONE, 2019, 14, e0220570.	1.1	20
244	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2541-2546.	1.2	93
245	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 1149-1160.	1.0	9

#	Article	IF	Citations
246	Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Lung Cancer, 2019, 136, 65-73.	0.9	8
247	Nonâ€"Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	1.4	1,153
248	<p>Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges</p>. OncoTargets and Therapy, 2019, Volume 12, 4605-4620.	1.0	22
249	Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. Journal of Cancer, 2019, 10, 3070-3078.	1.2	10
250	Programmed deathâ€"ligand 1 expression on direct Papâ€stained cytology smears from nonâ€"small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathology, 2019, 127, 470-480.	1.4	31
251	Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Nonâ€"small Cell Lung Cancer Recurrence. Clinical Lung Cancer, 2019, 20, 391-396.	1.1	36
252	Programmed death ligandâ€1/programmed deathâ€1 inhibition therapy and programmed death ligandâ€1 expression in urothelial bladder carcinoma. Chronic Diseases and Translational Medicine, 2019, 5, 170-177.	0.9	3
253	Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study. Lung Cancer, 2019, 137, 94-99.	0.9	10
254	The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PDâ€L1 expression and tumorâ€infiltrating lymphocytes. Cancer Medicine, 2019, 8, 7207-7218.	1.3	35
255	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	2.0	7
256	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	3.2	50
257	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinaseâ€positive nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 2117-2123.	0.8	9
258	Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. Cancers, 2019, 11, 1217.	1.7	36
259	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2019, 136, 45-51.	0.9	84
260	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 2019, 11, 1271.	1.7	27
261	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. BioMed Research International, 2019, 2019, 1-7.	0.9	20
262	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. International Journal of Molecular Sciences, 2019, 20, 4794.	1.8	29
263	Measuring tumor mutation burden in cell-free DNA: advantages and limits. Translational Lung Cancer Research, 2019, 8, 553-555.	1.3	4

#	Article	IF	Citations
264	Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer . Therapeutics and Clinical Risk Management, 2019, Volume 15, 605-612.	0.9	2
265	Cell‐blocks are suitable material for programmed cell death ligand‐1 immunohistochemistry: Comparison of cell‐blocks and matched surgical resection specimens in lung cancer. Cytopathology, 2019, 30, 578-585.	0.4	15
266	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer, 2019, 134, 167-173.	0.9	9
267	Assessing the interactions between radiotherapy and antitumour immunity. Nature Reviews Clinical Oncology, 2019, 16, 729-745.	12.5	183
268	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. Clinical and Translational Radiation Oncology, 2019, 17, 32-39.	0.9	14
269	Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study. British Journal of Cancer, 2019, 120, 1033-1036.	2.9	66
270	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. Clinical Lung Cancer, 2019, 20, 363-369.e2.	1.1	28
271	Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. Frontiers in Immunology, 2019, 10, 867.	2.2	36
272	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. Cancer Treatment Reviews, 2019, 76, 51-56.	3.4	36
273	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1915.	1.8	61
274	Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients. Nature Communications, 2019, 10, 1772.	5.8	149
275	Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. Cancer Cytopathology, 2019, 127, 447-457.	1.4	12
276	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65.		108
277	The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery. Molecular Oncology, 2019, 13, 1166-1179.	2.1	57
278	Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD‐L1 antibodies. Molecular and Clinical Oncology, 2019, 10, 391-396.	0.4	3
279	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. British Journal of Cancer, 2019, 120, 1003-1006.	2.9	109
280	Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. Clinical Lung Cancer, 2019, 20, 258-262.e1.	1.1	23
281	Early Phase I Study of a ^{99m}Tc-Labeled Anti‐Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non‐Small Cell Lung Cancer. Journal of Nuclear Medicine, 2019, 60, 1213-1220.	2.8	111

#	Article	IF	Citations
282	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunology, Immunotherapy, 2019, 68, 341-352.	2.0	82
283	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. Journal of Thoracic Disease, 2019, 11, S89-S101.	0.6	52
284	The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. Journal of Thoracic Disease, 2019, 11, S57-S64.	0.6	40
285	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. Translational Lung Cancer Research, 2019, 8, S323-S326.	1.3	6
286	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. Immuno-Oncology Technology, 2019, 4, 1-7.	0.2	2
287	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiology Imaging Cancer, 2019, 1, e190031.	0.7	22
288	<p>Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report</p>. OncoTargets and Therapy, 2019, Volume 12, 8595-8600.	1.0	23
289	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
290	Identifying successful biomarkers for patients with non-small-cell lung cancer. Lung Cancer Management, 2019, 8, LMT17.	1.5	7
291	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0
292	Assessment of Programmed Death–Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non–Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2019, 151, 403-415.	0.4	29
293	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD‐1/PD‐L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 105-115.	0.9	16
294	Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. In Vivo, 2019, 33, 213-220.	0.6	15
295	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 2019, 30, 44-56.	0.6	1,742
296	<scp>PD</scp>‐L1 and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268.	1.6	42
297	B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. OncoImmunology, 2019, 8, e1512458.	2.1	42
298	The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, e195-e207.	1.1	11
299	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168.	1.4	27

#	Article	IF	Citations
300	Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma. Oral Oncology, 2019, 89, 34-39.	0.8	33
301	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research, 2019, 25, 515-523.	3.2	354
302	Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas. Modern Pathology, 2019, 32, 511-523.	2.9	33
303	Tumor cell heterogeneity and resistance; report from the 2018 Coffey–Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	1.2	13
304	Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. Journal of Dermatological Science, 2019, 93, 33-40.	1.0	15
305	How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non–Small Cell Lung Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 11-12.	1.2	16
306	Digital and Computational Pathology for Biomarker Discovery. , 2019, , 87-105.		3
307	The value of immunotherapy in head and neck cancer. Expert Opinion on Biological Therapy, 2019, 19, 35-43.	1.4	14
308	Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 88-96.e6.	1.1	90
309	Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 107-113.	0.6	31
310	The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 287-294.	0.6	17
311	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. Pathology and Oncology Research, 2020, 26, 79-89.	0.9	59
312	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Modern Pathology, 2020, 33, 303-311.	2.9	65
313	High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. Annals of Surgical Oncology, 2020, 27, 933-942.	0.7	35
314	Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Modern Pathology, 2020, 33, 518-530.	2.9	61
315	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research, 2020, 26, 970-977.	3.2	200
316	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 261-271.	1.4	15
317	Intratumoral heterogeneity in programmed death–ligand 1 immunoreactivity is associated with variation in non–small cell lung carcinoma histotype. Histopathology, 2020, 76, 394-403.	1.6	17

#	Article	IF	Citations
318	Immunologic and immunogenomic aspects of tumor progression. Seminars in Cancer Biology, 2020, 60, 249-261.	4.3	35
319	Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 489-497.	1.8	38
320	Programmed death ligand 1 expression in EBUS aspirates of nonâ€"small cell lung cancer: Is interpretation affected by type of fixation?. Cancer Cytopathology, 2020, 128, 100-106.	1.4	20
321	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
322	Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. American Journal of Surgical Pathology, 2020, 44, 378-386.	2.1	23
323	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews, 2020, 82, 101925.	3.4	73
324	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarraysâ€™ and cross-validation with resections, in patients with, stage Iâ€"III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Modern Pathology, 2020, 33, 792-801.	2.9	28
325	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics, 2020, 10, 1708-1718.	4.6	68
326	PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Nonâ€"Small Cell Lung Cancers. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 437-443.	0.6	1
327	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 137-147.	1.0	6
328	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. American Journal of Surgical Pathology, 2020, 44, 174-181.	2.1	52
329	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Nonâ€"Small Cell Lung Adenocarcinomas. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 23-29.	0.6	6
330	Comparability of PDâ€Ł1 immunohistochemistry assays for nonâ€smallâ€cell lung cancer: a systematic review. Histopathology, 2020, 76, 793-802.	1.6	34
331	Biomarkers that may predict response to immunotherapy in ovarian malignancies. Current Opinion in Obstetrics and Gynecology, 2020, 32, 84-90.	0.9	8
332	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. Journal of Clinical Pathology, 2020, 73, 423-430.	1.0	14
333	Adaptive Immune Resistance to Intravesical BCG in Nonâ€"Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	3.2	98
334	Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. Histopathology, 2020, 77, 67-78.	1.6	4
335	Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World Journal of Urology, 2020, 38, 2537-2545.	1.2	16

#	ARTICLE	IF	CITATIONS
336	Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine, 2020, 3, 44-53.	1.3	10
337	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621.	2.5	8
338	High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples. Translational Cancer Research, 2020, 9, 5819-5828.	0.4	6
339	<p>A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 11499-11504.	1.0	6
340	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€"Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562.	1.1	1
341	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. Seminars in Oncology, 2020, 47, 367-379.	0.8	6
342	The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 569202.	1.3	22
343	Antifade Carbon Dots on a Plasmonic Substrate for Enhanced Protein Detection in Immunotherapy. ACS Sensors, 2020, 5, 4027-4034.	4.0	7
344	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095299.	1.4	23
345	Response of Pembrolizumab Alone for Non-small Cell Lung Cancer With Brain Metastasis: A Case Report and Literature Review. Frontiers in Oncology, 2020, 10, 577159.	1.3	1
346	Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, e65-e67.	0.6	0
347	Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. Expert Opinion on Emerging Drugs, 2020, 25, 353-366.	1.0	5
348	Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. Heliyon, 2020, 6, e04117.	1.4	5
349	Expression of Immune Response Markers in Arab Patients With Lung Cancer. JCO Global Oncology, 2020, 6, 1218-1224.	0.8	4
350	Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1. Pathology Research and Practice, 2020, 216, 153238.	1.0	2
351	Validity of whole genomes sequencing results in neoplasms in precision medicine. Journal of Clinical Pathology, 2020, 74, jclinpath-2020-206998.	1.0	5
352	Promising predictors of checkpoint inhibitor response in NSCLC. Expert Review of Anticancer Therapy, 2020, 20, 931-937.	1.1	15
353	An update on the immune landscape in lung and head and neck cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 505-517.	157.7	93

#	Article	IF	Citations
354	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Theranostics, 2020, 10, 10838-10848.	4.6	39
355	<p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of <sup>18</sup>F-FDG PET/CT</p>. Cancer Management and Research, 2020, Volume 12, 6385-6395.	0.9	11
356	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Theranostics, 2020, 10, 9395-9406.	4.6	16
357	Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095480.	1.4	9
358	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 517-524.	1.0	18
359	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 8229.	1.8	7
360	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. Breast Care, 2020, 15, 470-480.	0.8	11
361	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 2020, 9, 2393.	1.8	31
362	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. British Journal of Clinical Pharmacology, 2020, 86, 1736-1752.	1.1	10
363	Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole‐slide images. Cancer Medicine, 2020, 9, 4864-4875.	1.3	14
364	Molecular imaging for cancer immunotherapy. Immuno-Oncology Technology, 2020, 5, 10-21.	0.2	15
365	Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198.	0.4	19
366	Paclitaxel/sunitinib-loaded micelles promote an antitumor response <i>in vitro</i> through synergistic immunogenic cell death for triple-negative breast cancer. Nanotechnology, 2020, 31, 365101.	1.3	27
367	Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Disease Markers, 2020, 2020, 1-11.	0.6	9
368	Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. Nanomaterials, 2020, 10, 1145.	1.9	21
369	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Scientific Reports, 2020, 10, 9705.	1.6	57
370	Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma. Diagnostics, 2020, 10, 394.	1.3	4
371	PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 22, 83-87.	0.9	7

#	ARTICLE	IF	CITATIONS
372	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceutical Medicine, 2020, 34, 83-91.	1.0	9
373	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 55-60.	1.3	18
374	Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. Frontiers in Oncology, 2020, 10, 137.	1.3	53
375	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. International Journal of Molecular Sciences, 2020, 21, 4691.	1.8	40
376	Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23.	2.8	47
377	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	1.7	17
378	Small but powerful: the promising role of small specimens for biomarker testing. Journal of the American Society of Cytopathology, 2020, 9, 450-460.	0.2	14
379	Development and applications of computer image analysis algorithmsÂforÂscoring of PD-L1 immunohistochemistry. Immuno-Oncology Technology, 2020, 6, 2-8.	0.2	26
380	The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77.	2.6	89
381	Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma. Pathology, 2020, 52, 538-545.	0.3	7
382	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers, 2020, 12, 1800.	1.7	12
383	<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 667-683.	1.0	24
384	Imaging Responses to Immunotherapy with Novel PET Tracers. Journal of Nuclear Medicine, 2020, 61, 641-642.	2.8	7
385	Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. Japanese Journal of Clinical Oncology, 2020, 50, 800-809.	0.6	12
386	Quantitative image analysis for CD 8 score in lung small biopsies and cytology cellâ€blocks. Cytopathology, 2020, 31, 393-401.	0.4	3
387	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology, 2020, 157, 260-267.	0.6	32
388	Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular Cancer, 2020, 19, 19.	7.9	180
389	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. Journal of Cancer, 2020, 11, 551-558.	1.2	7

#	Article	IF	Citations
390	Computational analysis of morphological and molecular features in gastric cancer tissues. Cancer Medicine, 2020, 9, 2223-2234.	1.3	9
393	Advances in theranostic biomarkers for tumor immunotherapy. Current Opinion in Chemical Biology, 2020, 56, 79-90.	2.8	27
394	Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. BMC Cancer, 2020, 20, 344.	1.1	13
395	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in *EGFR/ALK* wild-type advanced non-small cell lung cancer. , 2020, 8, e000376.		111
396	Performance of Ventana SP263 PD‑L1 assay in endobronchial ultrasound guided‑fine ‑needle aspiration derived non‑small ‑cell lung carcinoma samples. Diagnostic Cytopathology, 2021, 49, 355-362.	0.5	6
397	Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma. Human Pathology, 2021, 108, 12-21.	1.1	2
398	Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World Journal of Urology, 2021, 39, 1319-1329.	1.2	30
399	In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Molecular Imaging and Biology, 2021, 23, 241-249.	1.3	23
400	Interobserver agreement in programmed cell death‑ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens. Diagnostic Cytopathology, 2021, 49, 219-225.	0.5	10
401	Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 1063-1074.	2.0	10
402	[89]Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression. Journal of Nuclear Medicine, 2021, 62, 656-664.	2.8	22
403	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 31-44.	1.4	23
404	Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer. Cancers, 2021, 13, 506.	1.7	9
405	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098406.	1.4	8
406	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0
407	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341.	1.6	17
408	Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics, 2021, 11, 3089-3108.	4.6	207
409	Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11.	0.0	0

#	Article	IF	Citations
410	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 544339.	1.3	18
411	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 2021, 53, 141-156.	0.3	126
412	PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. European Journal of Cancer, 2021, 144, 317-325.	1.3	13
413	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
414	Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 551367.	1.3	4
415	The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?. Turkish Journal of Medical Sciences, 2021, 51, 204-213.	0.4	3
416	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. Frontiers in Immunology, 2020, 11, 617583.	2.2	20
417	Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours. Endocrine Connections, 2021, 10, 180-190.	0.8	7
418	Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. Microorganisms, 2021, 9, 603.	1.6	11
419	Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes. Nature Communications, 2021, 12, 1613.	5.8	114
420	Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 479-493.	0.6	28
421	A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement. , 2021, 12, 111.		2
422	The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma. Molecules, 2021, 26, 1392.	1.7	21
423	The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%. Precision Cancer Medicine, 0, 4, 9-9.	1.8	1
424	The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study. Aging, 2021, 13, 9665-9678.	1.4	8
425	Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients. Annals of Translational Medicine, 2021, 9, 397-397.	0.7	0
426	Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. Oncology, 2021, 99, 464-470.	0.9	11
427	Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 611012.	1.3	16

#	Article	IF	Citations
428	PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. OncoTargets and Therapy, 2021, Volume 14, 2301-2309.	1.0	6
429	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. Cancers, 2021, 13, 1634.	1.7	23
430	EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non–Small Cell Lung Cancer. Cancers, 2021, 13, 2084.	1.7	21
431	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	4.3	70
432	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Scientific Reports, 2021, 11, 7830.	1.6	50
433	Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer. Annals of Diagnostic Pathology, 2021, 51, 151701.	0.6	4
434	Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 667-673.	0.6	11
435	Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer. Clinical Cancer Research, 2021, 27, 4139-4141.	3.2	1
436	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. Progress in Retinal and Eye Research, 2022, 86, 100971.	7.3	35
437	Dual-scale categorization based deep learning to evaluate programmed cell death ligand 1 expression in non-small cell lung cancer. Medicine (United States), 2021, 100, e25994.	0.4	6
438	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers, 2021, 13, 3083.	1.7	9
439	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncology, 2021, 17, 1987-2003.	1.1	23
440	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes. , 0, , .		0
441	Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. Npj Precision Oncology, 2021, 5, 52.	2.3	24
442	First-Line Treatment Options for PD-L1–Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 657545.	1.3	6
443	Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine, 2021, 9, 1040-1040.	0.7	3
444	Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer. Journal of Translational Medicine, 2021, 19, 249.	1.8	3
445	The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 3193-3204.	0.5	3

#	Article	IF	Citations
446	Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research, 2021, 9, 49.	2.8	53
447	Study of ^{89}Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2022, 63, 362-367.	2.8	44
448	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. Journal of the National Cancer Institute, 2022, 114, 664-675.	3.0	31
449	PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis. Journal of Thoracic Disease, 2021, 13, 4360-4370.	0.6	3
450	PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature. Acta Cytologica, 2021, 65, 501-509.	0.7	9
451	An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer. Anticancer Research, 2021, 41, 3925-3931.	0.5	13
452	First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients. Journal of Nuclear Medicine, 2022, 63, 536-542.	2.8	56
453	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2021, 16, 1086-1098.	0.5	53
454	Predictive value of 3′-deoxy-3′-^{18}F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. , 2021, 9, e003079.		5
455	Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients. Radiologia Medica, 2021, 126, 1425-1433.	4.7	34
456	Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic. Frontiers in Oncology, 2021, 11, 698425.	1.3	14
457	Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Frontiers in Oncology, 2021, 11, 620246.	1.3	38
458	Multifunctional Nanocarriers–Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. Advanced NanoBiomed Research, 2021, 1, 2100010.	1.7	5
459	Expression of immune checkpoint PD‑1 in non‑small cell lung cancer is associated with tumor cell DNA‑dependent protein kinase. Molecular and Clinical Oncology, 2021, 15, 211.	0.4	6
460	Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934. Modern Pathology, 2022, 35, 326-332.	2.9	15
461	Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens. Pathology, 2021, 53, 586-594.	0.3	10
462	Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncology, 2021, 119, 105368.	0.8	15
463	N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 718644.	1.3	15

#	ARTICLE	IF	CITATIONS
464	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1481-1492.	0.6	7
465	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp>â€8. Journal of Pathology, 2021, 255, 190-201.	2.1	49
466	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. Frontiers in Oncology, 2021, 11, 727433.	1.3	57
467	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. , 2021, 38, 287-295.		6
468	PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis. Cancers, 2021, 13, 4562.	1.7	2
469	Glial and myeloid heterogeneity in the brain tumour microenvironment. Nature Reviews Cancer, 2021, 21, 786-802.	12.8	83
470	Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Modern Pathology, 2022, 35, 403-411.	2.9	28
471	PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Nonâ€"small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2021, 22, 423-431.	1.1	34
472	Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. Annals of Oncology, 2021, 32, 1618-1625.	0.6	15
473	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
474	A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Nonâ€'Small Cell Lung Cancer. Advances in Anatomic Pathology, 2021, 28, 439-445.	2.4	7
475	A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis. Molecular Cancer, 2021, 20, 11.	7.9	26
476	The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. International Immunopharmacology, 2020, 80, 106247.	1.7	28
477	Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. International Immunopharmacology, 2020, 85, 106613.	1.7	24
479	Utility of CT radiomics for prediction of PDâ€L1 expression in advanced lung adenocarcinomas. Thoracic Cancer, 2020, 11, 993-1004.	0.8	56
480	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	3.9	94
481	High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. ERJ Open Research, 2021, 7, 00787-2020.	1.1	2
483	PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. World Journal of Meta-analysis, 2019, 7, 101-109.	0.1	7

#	ARTICLE	IF	CITATIONS
484	Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 119-130.	1.6	39
485	Prognostic value of *PDL1* expression in pancreatic cancer. Oncotarget, 2016, 7, 71198-71210.	0.8	81
486	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget, 2017, 8, 54722-54734.	0.8	39
487	Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. Oncotarget, 2017, 8, 64283-64293.	0.8	9
488	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget, 2018, 9, 5652-5664.	0.8	105
489	Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget, 2018, 9, 20769-20780.	0.8	20
490	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
491	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
492	Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology. Annals of Translational Medicine, 2017, 5, 265-265.	0.7	5
493	Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Annals of Translational Medicine, 2017, 5, 380-380.	0.7	12
494	PD-L1 as a biomarker in NSCLC: challenges and future directions. Annals of Translational Medicine, 2017, 5, 375-375.	0.7	35
495	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 351-351.	0.7	14
496	Immunotherapy for head and neck cancer: where are we now and where are we going?. Annals of Translational Medicine, 2019, 7, S75-S75.	0.7	35
497	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
498	Radiomics to predict response to immunotherapy: an imminent reality?. Future Oncology, 2020, 16, 1673-1676.	1.1	2
499	[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiology and Oncology, 2020, 54, 285-294.	0.6	48
500	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Frontiers in Immunology, 2020, 11, 596825.	2.2	53
501	Biomarkers for hepatocellular carcinoma: What's new on the horizon?. World Journal of Gastroenterology, 2018, 24, 3974-3979.	1.4	34

#	Article	IF	Citations
502	Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. Molecular and Clinical Oncology, 2020, 13, 43-47.	0.4	12
503	A subset of patients with MSS/MSIâ€‘lowâ€‘colorectal cancer showed increased CD8(+) TILs together with upâ€‘regulated IFNâ€Î³. Oncology Letters, 2019, 18, 5977-5985.	0.8	33
504	The daily practice reality of PDâ€L1 (CD274) evaluation in nonâ€‘small cell lung cancer: A retrospective study. Oncology Letters, 2020, 19, 3400-3410.	0.8	6
505	Mechanistic insight of predictive biomarkers for antitumor PDâ€1/PDâ€L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437.	1.2	18
506	Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting. Journal of Family Medicine and Primary Care, 2020, 9, 4086.	0.3	2
507	Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. Journal of Pathology Informatics, 2019, 10, 24.	0.8	70
508	Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. Immune Network, 2020, 20, e27.	1.6	36
509	Prolonged Response to Antiâ€"PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 644-648.	2.3	14
510	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
511	Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters. Journal of Pathology and Translational Medicine, 2021, 55, 398-405.	0.4	1
512	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 1355-1370.	1.1	6
513	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 326.	3.5	19
514	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Scientific Reports, 2021, 11, 19712.	1.6	54
515	Immunotherapeutic Advances for NSCLC. Biologics: Targets and Therapy, 2021, Volume 15, 399-417.	3.0	9
516	Efficacy of Immune Checkpoint Inhibitors in Lung Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2017, 13, 145-149.	0.0	0
517	ImmunoPET/CT imaging for assessing radiation-induced PD-L1 upregulation and its clinical application in head and neck cancer. Japanese Journal of Head and Neck Cancer, 2017, 43, 333-338.	0.0	0
518	Predictive Biomarkers for Squamous Cell Carcinoma. Molecular Pathology Library, 2018, , 173-175.	0.1	0
520	PD-L1 and Immunotherapy in Patients with Non-Small Cell Lung Cancer and Malignant Pleural Effusion. , 2018, , .		0

#	Article	IF	Citations
521	Clinical features of 10 patients with recurrent and/or metastatic head and neck carcinomas treated by Nivolumab:. Journal of Japan Society for Head and Neck Surgery, 2019, 28, 313-318.	0.0	1
522	PD-1é˜»å®³å‰¤ï¼ˆéᵢéƒ¨ç™Œï¼‰. Nihon Kikan Shokudoka Gakkai Kaiho, 2020, 71, 338-340.	0.0	1
523	Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. International Journal of Molecular Sciences, 2021, 22, 11563.	1.8	16
524	A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 720013.	1.1	6
526	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
527	Automated Tumor Proportion Scoring forÂAssessment of PD-L1 Expression Based on Multi-Stage Ensemble Strategy. Lecture Notes in Computer Science, 2020, , 70-79.	1.0	0
529	Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037812.	2.9	8
530	Terahertz toroidal metasurface biosensor for sensitive distinction of lung cancer cells. Nanophotonics, 2021, 11, 101-109.	2.9	74
533	Glycosylation of Siglec15 promotes immunoescape and tumor growth. American Journal of Cancer Research, 2021, 11, 2291-2302.	1.4	0
534	A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 769272.	1.3	23
535	Theranostics of Hematologic Disorders. , 2022, , 359-432.		0
536	Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer. PLoS ONE, 2021, 16, e0260988.	1.1	8
537	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Advances in Experimental Medicine and Biology, 2021, 1342, 45-80.	0.8	2
538	Biomarkers for predicting the efficacy of immune checkpoint inhibitors. Journal of Cancer, 2022, 13, 481-495.	1.2	12
539	Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis. Translational Cancer Research, 2020, 9, 5508-5516.	0.4	2
540	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
541	Immunotherapy using PDâ€‘1/PDL-1 inhibitors in tripleâ€‘negative breast cancer: a systematic review. Oncology Reviews, 2021, 15, 497.	0.8	8
542	A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. OncoImmunology, 2022, 11, 2028962.	2.1	26

#	Article	IF	Citations
543	Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by ⁸⁹Zr Immuno-PET. Molecular Imaging, 2022, 2022, 4906934.	0.7	6
544	Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker. Scientific Reports, 2022, 12, 192.	1.6	8
545	CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patientsâ€™ Survival. Cancer Investigation, 2022, 40, 228-233.	0.6	4
546	Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. Journal of Nanobiotechnology, 2022, 20, 64.	4.2	5
547	Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer. BMC Cancer, 2022, 22, 154.	1.1	1
548	Efficacy of Bivalent <i>CEACAM6/4-1BBL</i> Genetic Vaccine Combined with Anti-PD1 Antibody in MC38 Tumor Model of Mice. SSRN Electronic Journal, 0, , .	0.4	0
549	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. Antibody Therapeutics, 2022, 5, 73-83.	1.2	5
550	Deep Learning for Predicting Major Pathological Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer: A Retrospective Multicenter Study. SSRN Electronic Journal, 0, , .	0.4	0
551	Biomarkers of response to PD-1 pathway blockade. British Journal of Cancer, 2022, 126, 1663-1675.	2.9	52
552	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Frontiers in Oncology, 2022, 12, 847350.	1.3	6
553	VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?. Cancers, 2022, 14, 1006.	1.7	2
554	Self-Assembly of Podophyllotoxin-Loaded Lipid Bilayer Nanoparticles for Highly Effective Chemotherapy and Immunotherapy via Downregulation of Programmed Cell Death Ligand 1 Production. ACS Nano, 2022, 16, 3943-3954.	7.3	14
555	Review on Immuno-Oncology Agents for Cancer Therapy. Research Journal of Pharmacology and Pharmacodynamics, 2022, , 47-52.	0.1	1
556	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. Translational Lung Cancer Research, 2022, 11, 440-451.	1.3	12
557	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. Journal of Liver Cancer, 2022, 22, 40-50.	0.3	0
558	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. Clinical and Experimental Immunology, 2022, , .	1.1	1
559	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clinical Immunology, 2022, 237, 108962.	1.4	16
560	PDâ€L1 immunohistochemistry: Clones, cutoffs, and controversies. Apmis, 2022, 130, 295-313.	0.9	10

#	ARTICLE	IF	CITATIONS
561	Prediction of tumor mutation burden from H&E whole-slide images: a comparison of training strategies with convolutional neural networks. , 2022, , .		0
562	Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC. Frontiers in Immunology, 2022, 13, 828560.	2.2	18
563	Clinical tissue biomarker digital image analysis: A review of current applications. Human Pathology Reports, 2022, 28, 300633.	0.1	3
564	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology, 2021, 11, 803133.	1.3	83
565	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. Translational Cancer Research, 2021, 10, 5406-5429.	0.4	4
566	Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset. Bioengineered, 2021, 12, 10366-10378.	1.4	3
567	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0
568	Review on Immuno-Oncology agents for Cancer Therapy. Asian Journal of Pharmaceutical Research, 2022, , 110-115.	0.2	1
569	The â€œdigital biopsyâ€•in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3401-3411.	3.3	19
570	Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology and Hepatology, 2022, 16, 333-339.	1.4	65
573	Development of an immunohistochemical assay for Siglec-15. Laboratory Investigation, 2022, 102, 771-778.	1.7	8
576	A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. Frontiers in Immunology, 2022, 13, 859323.	2.2	25
577	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma. Frontiers in Genetics, 2022, 13, 863796.	1.1	0
578	Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout. Archives of Pathology and Laboratory Medicine, 2023, 147, 62-70.	1.2	2
579	Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature. Journal of Clinical Medicine, 2022, 11, 2629.	1.0	6
580	TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC. Frontiers in Pharmacology, 2022, 13, .	1.6	2
581	Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development, 2022, 7, 50-57.	0.4	1
582	Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer. Scientific Reports, 2022, 12, .	1.6	1

#	Article	IF	Citations
583	The risk of PD-L1 expression misclassification in triple-negative breast cancer. Breast Cancer Research and Treatment, 0, , .	1.1	1
584	Cancer germline antigen gene MAGEB2 promotes cell invasion and correlates with immune microenvironment and immunotherapeutic efficiency in laryngeal cancer. Clinical Immunology, 2022, 240, 109045.	1.4	9
585	Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology, 2022, , 100936.	0.6	1
586	Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2022, 11, 3245.	1.0	8
587	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
588	Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1747-1754.	1.2	2
589	Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy. Scientific Reports, 2022, 12, .	1.6	6
590	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	2.0	1
591	Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. Quantitative Imaging in Medicine and Surgery, 2022, 12, 4474-4487.	1.1	5
592	Chemical-induced lung tumor in Tg-rasH2 mice: a novel mouse tumor model to assess immune checkpoint inhibitors combined with a chemotherapy drug. Journal of Toxicologic Pathology, 2022, , .	0.3	0
593	18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology, 2022, 304, 246-264.	3.6	14
594	Primary pulmonary lymphoepithelioma–like carcinoma treated with immunotherapy: A case report and literature review. Thoracic Cancer, 0, , .	0.8	4
595	Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes, 2022, 13, 1204.	1.0	7
596	Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study. Annals of Surgical Oncology, 2022, 29, 7400-7406.	0.7	4
597	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	3
598	Immune-based combination therapy to convert immunologically cold tumors into hotÂtumors: an update and new insights. Acta Pharmacologica Sinica, 2023, 44, 288-307.	2.8	14
599	Preclinical antibody-PET imaging of PD-L1. Frontiers in Nuclear Medicine, 0, 2, .	0.7	0
600	Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. Investigational New Drugs, 2022, 40, 1282-1289.	1.2	7

#	Article	IF	Citations
601	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
602	PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients withâ€‰<â€‰1% PD-L1 expression: a meta-analysis of randomized controlled trials. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	3
603	Novel approaches for treatment of endometrial carcinoma. Current Problems in Cancer, 2022, 46, 100895.	1.0	7
604	Concordance of PD-L1 expression in triple-negative breast cancers in Chinese patients: A retrospective and pathologist-based study. Pathology Research and Practice, 2022, 238, 154137.	1.0	1
605	Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data. Translational Oncology, 2022, 25, 101526.	1.7	4
606	Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitorâ€"a Danish cohort study. Translational Lung Cancer Research, 2022, 11, 1796-1808.	1.3	1
607	Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastasesâ€"a Single-Center Study in 190 Patients. JTO Clinical and Research Reports, 2022, 3, 100413.	0.6	1
608	Molecular Biomarkers of Response to Cancer Immunotherapy. Clinics in Laboratory Medicine, 2022, 42, 469-484.	0.7	3
609	Biomarkers and immunotherapy: where are we?. Current Opinion in Oncology, 2022, 34, 579-586.	1.1	6
610	Extracellular vesicle-based checkpoint regulation and immune state in cancer. , 2022, 39, .		10
611	Efficacy of bivalent CEACAM6/4-1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice. Heliyon, 2022, 8, e10775.	1.4	0
612	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. Frontiers in Oncology, 0, 12, .	1.3	9
613	SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of <i>PD1</i> mRNA. Future Oncology, 0, , .	1.1	3
614	Cancer Immunotherapy Clinical Trials. , 2022, , 1-24.		0
615	Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. Frontiers in Genetics, 0, 13, .	1.1	1
616	T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer. Medicine (United States), 2022, 101, e31307.	0.4	3
617	Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine and Pharmacotherapy, 2022, 156, 113906.	2.5	36
618	The second near-infrared window quantum dot-based fluorescence anisotropy probes for separation-free, sensitive and rapid detection of small extracellular vesicle PD-L1 in plasma samples. Sensors and Actuators B: Chemical, 2023, 376, 132962.	4.0	3

#	ARTICLE	IF	CITATIONS
619	Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study. Academic Radiology, 2023, 30, 1317-1328.	1.3	4
620	Comparison of 22C3-PD-L1 Expression Between Paired Tumor Paraffin Blocks of Surgical Resection Specimens of Nonsmall Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 0, Publish Ahead of Print, .	0.6	0
621	Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. European Medical Journal (Chelmsford, England), 0, , 100-107.	3.0	0
622	Predictive biomarkers of colon cancer immunotherapy: Present and future. Frontiers in Immunology, 0, 13, .	2.2	30
624	Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity. BMJ Case Reports, 2022, 15, e252590.	0.2	1
625	Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma. Cancer Science, 0, , .	1.7	1
626	Study of the clinicopathological features of soluble PD-L1 in lung cancer patients. Journal of Rural Medicine: JRM, 2023, 18, 42-49.	0.2	0
627	Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. Bioengineered, 2022, 13, 14872-14888.	1.4	5
628	Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. Cancers, 2023, 15, 180.	1.7	0
630	Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. Journal of Mathematical Biology, 2023, 86, .	0.8	0
631	Examining the Efficacy of Nivolumab for Gastric Cancer Focusing on Using an Inflammation-based Prognostic Score: A Multicenter Retrospective Study. Anticancer Research, 2023, 43, 927-934.	0.5	0
632	Assessing PD-L1 Expression in Different Tumor Types. , 2023, , 1-21.		0
633	Albumin–derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study. In Vivo, 2023, 37, 818-824.	0.6	0
634	The diverse pancreatic tumor cell-intrinsic response to IFNÎ³ is determined by epigenetic heterogeneity. Cancer Letters, 2023, 562, 216153.	3.2	1
635	A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. Journal of Thoracic Oncology, 2023, 18, 718-730.	0.5	8
636	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 3618.	1.8	6
637	Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports. Expert Opinion on Investigational Drugs, 2023, 32, 187-200.	1.9	1
638	Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2023, 46, 161-166.	0.6	2

#	Article	IF	Citations
639	Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer, 2023, 22, .	7.9	29
640	Comparative evaluation of <scp><i>PD‐L1</i></scp> expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients. Molecular Oncology, 2023, 17, 737-746.	2.1	3
641	Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, .	0.0	0
642	Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti‐programmed cell death‐1 therapy. Cancer Medicine, 2023, 12, 11334-11343.	1.3	1
643	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology, 2023, 14, .	0.8	2
644	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 6710.	1.8	7
645	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194.	2.4	0
646	C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Disease, 2023, .	0.6	1
692	PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer. , 2024, , 65-86.		0